Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$22.96 -0.9%	$24.77	$20.92 ▼ $42.48	$43.87B	N/A	198,493 shs	192,711 shs
GSK GSK	$38.59 +0.8%	$38.81	$31.72 ▼ $44.67	$78.37B	0.52	4.90 million shs	4.77 million shs
SNY Sanofi	$48.37 +1.2%	$51.01	$45.80 ▼ $60.12	$117.23B	0.5	2.34 million shs	1.93 million shs
TAK Takeda Pharmaceutical	$15.09 +0.8%	$14.82	$12.80 ▼ $15.43	$47.63B	0.23	1.96 million shs	1.78 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	-1.03%	-3.61%	-14.62%	-6.23%	-34.44%
GSK GSK	+0.85%	-0.16%	-2.15%	-0.38%	-0.71%
SNY Sanofi	+1.19%	+1.57%	-7.67%	-13.35%	+0.08%
TAK Takeda Pharmaceutical	+0.70%	+1.21%	+2.76%	+0.20%	+16.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GSK GSK	2.0009 of 5 stars	1.1	4.0	2.5	0.0	1.9	0.0	2.5
SNY Sanofi	4.0313 of 5 stars	3.6	3.0	2.5	0.0	2.0	0.0	3.1
TAK Takeda Pharmaceutical	1.0976 of 5 stars	0.0	3.0	1.7	0.0	3.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
GSK GSK	2.10	Hold	$37.38	-3.16% Downside
SNY Sanofi	3.13	Buy	$61.50	27.14% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest DSNKY, SNY, GSK, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	DSNKY Daiichi Sankyo	Nomura Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/3/2025	SNY Sanofi	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
6/2/2025	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$56.00
4/28/2025	GSK GSK	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
4/28/2025	SNY Sanofi	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/15/2025	GSK GSK	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$35.25
4/15/2025	SNY Sanofi	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
4/2/2025	TAK Takeda Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSNKY Daiichi Sankyo	$12.39B	3.51	$1.24 per share	18.45	$5.61 per share	4.09
GSK GSK	$40.10B	1.97	$5.63 per share	6.86	$8.07 per share	4.78
SNY Sanofi	$44.46B	2.67	$5.39 per share	8.97	$33.20 per share	1.46
TAK Takeda Pharmaceutical	$30.09B	1.60	$3.20 per share	4.71	$14.39 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSNKY Daiichi Sankyo	$1.95B	$1.03	22.29	21.06	1.18	15.65%	17.92%	8.61%	7/29/2025 (Estimated)
GSK GSK	$3.29B	$1.94	19.89	8.30	1.34	9.89%	48.82%	11.15%	7/30/2025 (Estimated)
SNY Sanofi	$6.02B	$2.80	17.28	10.18	0.99	14.56%	17.15%	9.80%	7/24/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	68.57	9.14	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)

Latest DSNKY, SNY, GSK, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	SNY Sanofi	$0.98	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/25/2025	Q4 2025	DSNKY Daiichi Sankyo	N/A	$0.30	N/A	$0.30	N/A	$3.40 billion
4/24/2025	Q1 2025	SNY Sanofi	$0.90	$0.94	+$0.04	$0.80	$9.79 billion	$10.41 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A
GSK GSK	$1.69	4.38%	N/A	87.11%	N/A
SNY Sanofi	$1.60	3.31%	N/A	57.14%	N/A
TAK Takeda Pharmaceutical	$0.27	1.79%	N/A	122.73%	N/A

Latest DSNKY, SNY, GSK, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025
4/15/2025	SNY Sanofi	annual	$2.0369	3.1%	5/9/2025	5/9/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSNKY Daiichi Sankyo	0.06	2.53	1.85
GSK GSK	1.21	0.87	0.58
SNY Sanofi	0.16	1.37	0.69
TAK Takeda Pharmaceutical	0.57	1.01	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSNKY Daiichi Sankyo	N/A
GSK GSK	15.74%
SNY Sanofi	14.04%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
DSNKY Daiichi Sankyo	N/A
GSK GSK	10.00%
SNY Sanofi	1.00%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable
SNY Sanofi	82,878	2.45 billion	2.43 billion	Optionable
TAK Takeda Pharmaceutical	49,281	3.18 billion	3.18 billion	Optionable

DSNKY, SNY, GSK, and TAK Headlines

Recent News About These Companies

Lupin gets U.S. FDA nod for generic of Takeda’s constipation drug

June 25 at 2:36 PM | thehindu.com

Sun Pharma Announces Appointment of Richard Ascroft as CEO North America

June 25 at 2:36 PM | finance.yahoo.com

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

June 25 at 9:56 AM | zacks.com

Lupin gets approval from U.S FDA for Prucalopride Tablets

June 25 at 9:34 AM | uniindia.comU

Lupin receives USFDA approval for Prucalopride Tablets

June 25 at 4:32 AM | business-standard.comB

USFDA okays Lupin Prucalopride Tablets for chronic idiopathic constipation

June 25 at 4:32 AM | medicaldialogues.inM

Lupin receives US FDA approval for drug used to treat bowel disorder

June 25 at 4:32 AM | cnbctv18.comC

Takeda Announces New Assignments of Directors

June 25 at 3:07 AM | businesswire.com

Takeda Pharmaceutical Co Ltd ADR Key Metrics - Morningstar

June 24 at 6:30 PM | morningstar.comM

Alagille Syndrome Market Research 2025-2035 | Competitive Analysis of Mirum Pharmaceuticals, Ipsen, and Takeda Pharmaceutical

June 24 at 1:29 PM | uk.finance.yahoo.com

Questex’s Fierce Pharma Unveils Powerhouse Conference Program for the Inaugural Fierce Pharma Week, Where Pharma’s Future Takes Shape

June 23, 2025 | finance.yahoo.com

Yousif Capital Management LLC Has $444,000 Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK)

June 21, 2025 | marketbeat.com

Inscription Capital LLC Invests $303,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

June 19, 2025 | marketbeat.com

Wisner Baum: Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

June 18, 2025 | kxan.comK

Takeda Pharmaceutical Co. (NYSE:TAK) Shares Purchased by QRG Capital Management Inc.

June 18, 2025 | marketbeat.com

Trump rekindles pharmaceutical tariff threat, suggesting import duties could come 'very soon': Reuters

June 17, 2025 | fiercepharma.comF

Class Status Upheld in Takeda, Eli Lilly RICO Suit Over Actos

June 17, 2025 | news.bloomberglaw.comN

GAMMA Investing LLC Has $1.56 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 15, 2025 | marketbeat.com

Sun Pharma announce major leadership shake-up, names Kirti Ganorkar as MD, Shanghvi steps into executive Chairman Role

June 14, 2025 | moneycontrol.com

Sun Pharma names Kirti Ganorkar as new managing director, Dilip Shanghvi to continue as chairman

June 13, 2025 | msn.com

Wealth Enhancement Advisory Services LLC Lowers Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSNKY, SNY, GSK, and TAK Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

$22.96 -0.20 (-0.86%)

As of 06/26/2025 03:58 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

GSK NYSE:GSK

$38.59 +0.31 (+0.82%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$38.86 +0.27 (+0.69%)

As of 05:06 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Sanofi NASDAQ:SNY

$48.37 +0.57 (+1.19%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$48.47 +0.10 (+0.21%)

As of 05:05 AM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Takeda Pharmaceutical NYSE:TAK

$15.08 +0.12 (+0.77%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$15.06 -0.03 (-0.17%)

As of 06/26/2025 05:32 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time